TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.

Slides:



Advertisements
Similar presentations
CTI LIFE SCIENCES FUND Role of a VC in Helping Commercialize Early Stage Innovation November 19 th 2007 Presented by: Richard J. Meadows Managing Partner.
Advertisements

European RTD programmes and global benefits 6CP Workshop, Helsinki June 2004 Pirjo Kutinlahti & Marjo Uotila.
David M. Pollock Medical College of Georgia Discovery-Academia.
REGIONAL (TERRITORIAL) DEVELOPMENT
Diseases without borders What must the Global Development Community Do? World Bank Seminar Series Tawhid Nawaz, Operations Advisor Human Development Network.
February 2006 WHO's Contribution to Scaling Up towards Universal Access to HIV/AIDS Prevention, Care and Treatment Department of HIV/AIDS.
Professor Dave Delpy Chief Executive of Engineering and Physical Sciences Research Council Research Councils UK Impact Champion Competition vs. Collaboration:
Trends in TB R&D investment: Where is funding most needed? Lindsey Wu Policy Analyst Policy Cures
Pharmaceuticals and Global Health Inequalities and Innovation in the 21 st Century.
Renewing Health Canada’s strategy against TB for First Nations on-reserve Provincial Primary Care Tuberculosis Education Day October 28, 2011 Presented.
Biomedical Engineering Initiative: Creating the next generation of healthcare innovators in Africa Muhammad H. Zaman Director, LEED, Boston University.
PUBLIC HEALTH INNOVATION AND RESEARCH IN EUROPE AND THE UNITED KINGDOM EXPLORING THE BREADTH OF PUBLIC HEALTH RESEARCH FPH ANNUAL CONFERENCE 2012, CARDIFF.
Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.
Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.
Dr. E. Anne Peterson, MD, MPH Assistant Administrator, Bureau for Global Health, USAID Sustainable Investment and Donor Coordination Stop TB Partners Forum.
Michel Goldman, Executive Director Innovative Medicines Initiative (IMI)
Advancing Alternative Energy Technologies Glenn MacDonell Director, Energy Industry Canada Workshop on Alternatives to Conventional Generation Technologies.
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Virtual Collaborative Social Living Community for Elderly Kick Off Event WP 7 Plan 1 st period Inova+
PUTTING AN END TO TB WHERE ARE THE OPPORTUNITIES AND WHAT ARE THE CHALLENGES? STRATEGY MEETING ON RESOURCE MOBILIZATION FOR THE GLOBAL FUND TO FIGHT AIDS,
T reatment A ction G roup Update on Global TB Research By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis.
Welcome Rebecca Wood Chief Executive. Welcome Alzheimer’s Research UK.
APPMG BEAD meeting London, February 6, 2006 MALARIA VACCINES DEVELOPMENT: THE WAY AHEAD Joe Cohen, Ph.D. Vice President R&D Vaccines for Emerging Diseases.
Using the levy in order to finance recurring expenditures : the case of the International Drug Purchase Facility-UNITAID Meeting of experts on the solidarity.
Priority Medicines Project Background review Tuberculosis Dr Mary Moran London School of Economics September 2004.
The Global Fund- structure, function and evolution February 18, 2008.
TASK FORCE ON RETOOLING STOP TB PARTNERSHIP Cape Town November 2007.
WHO Expert Working Group on R&D Financing Stop TB New Tools Working Groups Marcos Espinal Executive Secretary.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
A new start for the Lisbon Strategy Knowledge and innovation for growth.
Research Funding 101 Coventry University | 7 th June 2014 | Dr Lynsey McCulloch.
September 13, 2007SGH&M2B International&Training Workshop What does the European Technology Platform “Innovative Medicines initiative” offer? Vitalijs.
An Introduction to the European Academy of Business in Society and the RESPONSE project Dr. Pablo Collazzo-Yelpo, EABIS Director, Academic Affairs Kiev.
Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.
End TB Strategy HCW with cough since January. Seen at government clinic thrice with no sputum/CXR. Diagnosed TB in May only.
The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.
Bob Jones Technical Director CERN - August 2003 EGEE is proposed as a project to be funded by the European Union under contract IST
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
What communities need from global and National stakeholders to ensure engagement of community groups. Francis George Apina 15 th Core Group meeting of.
THE REPUBLIC OF UGANDA National AIDS Conference Presentation during the 4 th Uganda AIDS partnership Forum, Munyonyo, 31 st January 2006 By James Kaboggoza-Ssembatya,
SA AIDS Conference Pre Conference session 06 June 2011 Strategic Partnerships through Social Dialogue in implementing HIV and AIDS Policies and Programmes:
DEVELOPMENT COOPERATION FRAMEWORK Presentation by Ministry of Finance 10 December 2013.
Dr. Shane Renwick, DVM, MSc, A/Director, Animal Health Science Division, Canadian Food Inspection Agency CAHLN, UCVM June 8, 2010 Foresight for Canadian.
Alexandra Heumber Médecins Sans Frontières Access to Essential Medicines Campaign DEBRIEFING WHA May 2006.
Professor Veena Sahajwalla ARC Laureate Fellow Director, Centre for Sustainable Materials Research & Technology Dealing with Industry Partners.
Access to drugs, Reducing bottlenecks Matt Cooper Business Development & Marketing Director NIHR Clinical Research Network
De Beers Response to HIV/AIDS 19 th June 2006 World Bank Group- CommDev Workshop.
Think Family Briefing for Governors Alison Smith, Together for Families Lead Officer V1.0.
Richard Escritt, Director – Coordination of Community Actions DG Research, European Commission “The development of the ERA: Experiences from FP6 and reflections.
Tuberculosis - the opportunity in our lifetime Dr. Lucica Ditiu | Executive Secretary | Stop TB Partnership 09.April.2013 | Brussels, Belgium.
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
Success Stories of Globalization in Korean Pharma
What is €5 billion worth? Magda Gunn, IMI Scientific Project Manager.
Alessandra Luchetti Deputy Head of Unit
Work Programme The social challenge “Health, Demographic Change and Wellbeing” Maia Okujava NCP for Health, Demographic Change and weii-being,
Finland, a Global Testbed for Personalized Cancer Research?
Accessing Medicines in Africa Prospects and challenges
World Health Organization
The Commission Strategy on TB vaccine research
Committee Task Statement (1)
World Health Organization
Innovative Medicines Initiative:
UKCRC Translational Infection Research Initiative
Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”
How do you start a collaborative response?
The STOP TB Strategy – 2009 VISION: A TB-free world
IMI – an opportunity to implement research for patients and with patients Catherine Brett European Parliament Interest Group on Allergy and Asthma
Presentation transcript:

TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB New Tools meeting HoC 23 rd June

Why are we here today? We all know the facts and figures about TB New tools urgently required:  Rapid, robust, reliable & accurate diagnostics  Vaccines  Key Biomarkers  New drugs

Why new TB drugs? Treatment takes 6 to 9 months Contributes to low compliance, resistance and relapse Co-infection with HIV/AIDS is limits the use of current drugs No new drugs since the 1960s! New drugs urgently needed to reduce treatment time, combat resistance and be compatible with HIV/AIDS sufferers

Broad spectrum antibiotics Drug regime for drug susceptible TB The Challenge !

State of the current development pipeline Long & Very complex with high rates of attrition Highly multi disciplinary Very expensive - £100s millions No commercial market to sustain the development pipeline Current strategy: TB Alliance is the “Global Coordinator” working with partners in academia and pharmaceutical industry UK can increase its’ established role within this strategy

State of the current Global development pipeline Early Stage Discovery Basic Science Identification of new “actives” Numerous projects in UK and globally from academia and pharmaceutical industry At least 30 known projects to discover new actives Exploratory Development Pre-clinical Clinical At least 6 known projects 8 projects at Phase I and II Full Development 3 projects including REMox-TB (UCL & St Andrews) at Phase III None at launch & phase IV (since 1960s) Start Finish Progressing BUT grossly insufficient

The UK perspective: TB Drug discovery UK (TBD-UK) Funded for 2 years in 2009 by the Medical Research Council UK wide consortia of academic and industrial partners involved in TB drug discovery and development research Goal: To engage the UK in coordinated research and maximise it’s contribution to global efforts to facilitate drug development and provide new drugs at the clinic

TBD-UK: What has been achieved so far? New class of anti-TB agent identified (others now integrated into TBD-UK) New basic science breakthrough discoveries in drug targets IMI-EU framework 7 pre-DICT consortia formed to support “models” Working TBD-UK blueprint created to guide all UK research Significant UK outreach with 40+ researchers engaged in collaboration International outreach via website

TBD-UK: Conclusion & Future direction UK science ready to integrate with DFID & BIS policy to make real impact Development of public private partnerships is a key factor Dialogue with pharmaceutical industry, MRC, NGOs, Charities and DFID essential to move forward and maximise UK potential APPG-TB round table meeting with all parties should be the next step to achieve our common goals in finding new TB drugs

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.